Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefepime + tazobactam + edetic acid
- Development stage
- Unknown
- Lead developer
- Venus Remedies
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Supime is a fixed-dose combination antibiotic developed by Venus Remedies, utilizing their proprietary Antibiotic Adjuvant Entity (AAE) technology. It consists of the fourth-generation cephalosporin **cefepime**, the beta-lactamase inhibitor **tazobactam**, and the adjuvant **edetic acid** (disodium edetate/EDTA). Cefepime acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), while tazobactam protects cefepime from degradation by inhibiting various beta-lactamase enzymes, including extended-spectrum beta-lactamases (ESBLs). The inclusion of edetic acid serves as an adjuvant that helps disrupt bacterial outer membranes and may inhibit metallo-beta-lactamases by chelating divalent cations. Supime is indicated for the treatment of serious infections such as nosocomial and community-acquired pneumonia, urinary tract infections, bacterial septicaemia, skin and soft tissue infections, and intra-abdominal infections, particularly those caused by multi-drug resistant (MDR) Gram-negative bacteria.
- Brand names
- Supime
- Other names
- Cefepime-Tazobactam-EDTACefepime/Tazobactam/EDTA
02
Targets
PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on cefepime + tazobactam + edetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefepime + tazobactam + edetic acid.